ICAT acts as a Coactivator in Regulating PPARγ Transcriptional Activity in Mesangial Cells

Abstract

Aims Our study aims to explore the role of β-catenin interaction protein-1(ICAT) in regulating peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity in mesangial cells. The abnormal ICAT expression in mesangial cells under high glucose(HG) contributes to the development of diabetes and its complications such as diabetic nephropathy (DN).

Methods Human mesangial cells (HMCs) were cultured in either 5.5 (normal control) or 30 (high glucose) mmol/L glucose medium. Overexpression and knock-down of ICAT or β-catenin were carried out by transient transfection. PPARγ transcriptional activity was evaluated by luciferase assay. Protein-protein interactions were tested by Coimmunoprecipitation and GST-pull down assay. Cell phenotype transition of HMCs was detected by the expression level of α-SMA and fibronectin, as well as MTT assay.

Results High β-catenin protein expression but low ICAT was accompanied by low PPARγ transcriptional activity in HMCs cultured in HG. By using bioinformatics prediction, protein-protein and protein-DNA interaction experimental methods, ICAT and β-catenin were confirmed to act as coactivators in regulating PPARγ transcriptional activity. Overexpression of ICAT could mitigate the decrease of PPARγ transcriptional activity and partly relieve cell phenotype transition in HMCs.

Conclusions β-catenin and ICAT interact as coactivator to modulate PPARγ transcriptional activation. In HMCs cultured in HG, the low expression of ICAT leads to low PPARγ transcriptional activation.

Key words

diabetic nephropathy - mesangial cells - peroxisome proliferator-activated receptor γ - β-catenin interaction protein-1

Publication History

Received: 21 June 2018
Received: 16 January 2019

Accepted: 18 March 2019

Article published online:
16 September 2020

• References

• 1 Xu Y, Wang L, He J. et al. Prevalence and control of diabetes in Chinese adults. Jama 2013; 310: 948-959
• 2 Vanholder R, Annemans L, Brown E. et al. Reducing the costs of chronic kidney disease while delivering quality health care: A call to action. Nat Rev Nephrol 2017; 13: 393-409
• 3 Yang J, Zhou Y, Guan Y. PPARgamma as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens 2012; 21: 97-105
• 4 Toffoli B, Gilardi F, Winkler C. et al. Nephropathy in Pparg-null mice highlights PPARgamma systemic activities in metabolism and in the immune system. PLoS One 2017; 12: e0171474
• 5 Flaquer M, Lloberas N, Franquesa M. et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci 2010; 87: 147-153
• 6 Yang J, Zhang D, Li J. et al. Role of PPARgamma in renoprotection in Type 2 diabetes: Molecular mechanisms and therapeutic potential. Clin Sci (Lond) 2009; 116: 17-26
• 7 Kahn M. Can we safely target the WNT pathway?. Nat Rev Drug Discov 2014; 13: 513-532
• 8 Liu Z, Habener JF. Wnt signaling in pancreatic islets. Adv Exp Med Biol 2010; 654: 391-419
• 9 Xiao L, Wang M, Yang S. et al. A glimpse of the pathogenetic mechanisms of Wnt/beta-catenin signaling in diabetic nephropathy. Biomed Res Int 2013; 2013: 987064
• 10 Mu J, Pang Q, Guo YH. et al. Functional implications of microRNA-215 in TGF-beta1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One 2013; 8: e58622
• 11 Tago K, Nakamura T, Nishita M. et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 2000; 14: 1741-1749
• 12 Zhuo M, Zhu C, Sun J. et al. The beta-catenin binding protein ICAT modulates androgen receptor activity. Mol Endocrinol 2011; 25: 1677-1688
• 13 Lu D, Cottam HB, Corr M. et al. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2005; 102: 18567-18571
• 14 Guo F, Ren X, Dong Y. et al. Constitutive expression of PPARgamma inhibits proliferation and migration of gastric cancer cells and down-regulates Wnt/beta-Catenin signaling pathway downstream target genes TERT and ENAH. Gene. 2016
• 15 Sabatino L, Pancione M, Votino C. et al. Emerging role of the beta-catenin-PPARgamma axis in the pathogenesis of colorectal cancer. World J Gastroenterol 2014; 20: 7137-7151
• 16 Liu J, Wang H, Zuo Y. et al. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 2006; 26: 5827-5837
• 17 Chen J, Guo Y, Zeng W. et al. ER stress triggers MCP-1 expression through SET7/9-induced histone methylation in the kidneys of db/db mice. Am J Physiol Renal Physiol 2014; 306: F916-F925
• 18 Nojima K, Sugimoto K, Ueda H. et al. Analysis of hepatic gene expression profile in a spontaneous mouse model of type 2 diabetes under a high sucrose diet. Endocr J 2013; 60: 261-274
• 19 Plantinga LC, Crews DC, Coresh J. et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673-682
• 20 Di Lullo L, Mangano M, Ronco C. et al. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes Metab Syndr. 2017
• 21 Martinez-Garcia C, Izquierdo A, Velagapudi V. et al. Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. Dis Model Mech 2012; 5: 636-648
• 22 Kusunoki H, Taniyama Y, Azuma J. et al. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-gamma/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension 2012; 59: 308–316 
• 23 Jenster G. Coactivators and corepressors as mediators of nuclear receptor function: An update. Mol Cell Endocrinol 1998; 143: 1-7
• 24 Naar AM, Lemon BD, Tjian R. Transcriptional coactivator complexes. Annu Rev Biochem 2001; 70: 475-501
• 25 Gustafson B, Smith U. Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem 2010; 285: 14031-14041
• 26 Kozinski K, Jazurek M, Dobrzyn P. et al. Adipose- and muscle-derived Wnts trigger pancreatic beta-cell adaptation to systemic insulin resistance. Sci Rep 2016; 6: 31553
• 27 Fuster JJ, Zuriaga MA, Ngo DT. et al. Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 2015; 64: 1235-1248
• 28 Lee MY, Hsiao PJ, Yang YH. et al. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: Bladder cancer and chronic kidney disease. PLoS One 2014; 9: e85479
• 29 Nauck MA, di Domenico M, Patel S. et al. Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diab Vasc Dis Res 2016; 13: 286-298
• 30 Yang XL, Duo-Ji MM, Long ZW. Efficacy and safety of single- or double-drug antidiabetic regimens in the treatment of type 2 diabetes mellitus: A network meta-analysis. J Cell Biochem 2017; 118: 4536-4547
• 31 Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia.. 2017
• 32 Tong JF, Yan X, Zhao JX. et al. Metformin mitigates the impaired development of skeletal muscle in the offspring of obese mice. Nutr Diabetes 2011; 1: e7
• 33 Takatani T, Minagawa M, Takatani R. et al. AMP-activated protein kinase attenuates Wnt/beta-catenin signaling in human osteoblastic Saos-2 cells. Mol Cell Endocrinol 2011; 339: 114-119
• 34 Banerjee P, Dutta S, Pal R. Dysregulation of Wnt-Signaling and a Candidate Set of miRNAs Underlie the Effect of Metformin on Neural Crest Cell Development. Stem Cells 2016; 34: 334-345
• 35 Zou YF, Xie CW, Yang SX. et al. AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/beta-catenin signaling pathway activity. Mol Med Rep 2017; 15: 899-907